We have reported that tyrosine-phosphorylated forms of a cellular protein, FKBP52, inhibit the second-strand DNA synthesis of adenoassociated virus 2 (AAV), leading to inefficient transgene expression from recombinant AAV vectors. To further explore the role of FKBP52 in AAV-mediated transduction, we established murine embryo fibroblasts (MEFs) cultures from FKBP52 wild-type (WT), heterozygous (HE), and knockout (KO) mice. Conventional AAV vectors failed to transduce WT MEFs efficiently, and the transduction efficiency was not significantly increased in HE or KO MEFs. AAV vectors failed to traffic efficiently to the nucleus in these cells. Treatment with hydroxyurea (HU) increased the transduction efficiency of conventional AAV vectors by ∼25-fold in WT MEFs, but only by ∼4-fold in KO MEFs. The use of selfcomplementary AAV (scAAV) vectors, which bypass the requirement of viral second-strand DNA synthesis, revealed that HU treatment increased the transduction efficiency ∼23-fold in WT MEFs, but only ∼4-fold in KO MEFs, indicating that the lack of HU treatment-mediated increase in KO MEFs was not due to failure of AAV to undergo viral second-strand DNA synthesis. Following HU treatment, ∼59% of AAV genomes were present in the nuclear fraction from WT MEFs, but only ∼28% in KO MEFs, indicating that the pathway by which HU treatment mediates nuclear transport of AAV was impaired in KO MEFs. When KO MEFs were stably transfected with an FKBP52 expression plasmid, HU treatmentmediated increase in the transduction efficiency was restored in these cells, which correlated directly with improved intracellular trafficking. Intact AAV particles were also shown to interact with FKBP52 as well as with dynein, a known cellular protein involved in AAV trafficking. These studies suggest that FKBP52, being a cellular chaperone protein, facilitates intracellular trafficking of AAV, which has implications in the optimal use of recombinant AAV vectors in human gene therapy.
Introduction
Adeno-associated virus 2 (AAV), a nonpathogenic human parvovirus, has gained attention as a potentially safe vector for gene transfer and gene therapy (Conlon and Flotte, 2004; Marshall, 2001) . The AAV genome is a single-stranded DNA (Berns and Giraud, 1996; Muzyczka, 1992) , which is Virology 353 (2006) 283 -293 www.elsevier.com/locate/yviro transcriptionally inactive. Others and we have suggested that viral second-strand DNA synthesis is the rate-limiting step in AAV-mediated transgene expression (Ferrari et al., 1996; Fisher et al., 1996; Mah et al., 1998; Qing et al., 1997 Qing et al., , 1998 Qing et al., , 2001 Qing et al., , 2003 Zhong et al., 2004a Zhong et al., , 2004b Zhong et al., , 2004c Zhong et al., , 2004d . In our previous studies, we have identified that a 52-kDa cellular protein, FKBP52, which binds the immunosuppressant drug, FK506, interacts specifically with the D-sequence within the inverted terminal repeat (ITR) of the AAV genome (Qing et al., 2001; Zhong et al., 2004a Zhong et al., , 2004b Zhong et al., , 2004c Zhong et al., , 2004d . FKBP52 is phosphorylated at both tyrosine and serine or threonine residues, and phosphorylated FKBP52 inhibits the viral second-strand DNA synthesis, leading to inefficient transgene expression Qing et al., 1997 Qing et al., , 1998 Qing et al., , 2001 Qing et al., , 2003 Zhong et al., 2004a Zhong et al., , 2004b Zhong et al., , 2004c Zhong et al., , 2004d . We have also documented that FKBP52 is dephosphorylated at tyrosine residues by the cellular T cell protein tyrosine phosphatase (TC-PTP), and dephosphorylated FKBP52 can no longer bind to the D-sequence, thereby allowing viral second-strand DNA synthesis and, consequently, efficient transgene expression (Qing et al., 2003; Zhong et al., 2004a Zhong et al., , 2004b Zhong et al., , 2004c Zhong et al., , 2004d . Our previous studies with FKBP52-knockout (FKBP52-KO) mice, in which FKBP52 is completely absent, documented that the transduction efficiency in hematopoietic stem/progenitor cells and hepatocytes was significantly less pronounced than that from TC-PTP-transgenic (TC-PTP-TG) mice, in which FKBP52 is dephoshorylated at tyrosine residues (Zhong et al., 2004a (Zhong et al., , 2004b (Zhong et al., , 2004c . We have also reported that AAV vectors transduce an established murine fibroblast cell line poorly due to impaired intracellular trafficking (Hansen et al., 2000 (Hansen et al., , 2001a , and that deliberate over-expression of FKBP52 significantly increases the transduction efficiency in these cells (Qing et al., 2001 ). Although we interpreted these data to suggest that over-expression of FKBP52 led to dephosphorylation at tyrosine residues of the endogenous FKBP52 in the nucleus, the precise role of FKBP52 in the cytoplasm remained unclear. This is of significance since FKBP52 has been documented to interact with HSP90 only when in the dephosphorylated form, and this complex has been shown to mediate cytoplasmic transport of a number of cellular and viral proteins to the nucleus (Czar et al., 1994a (Czar et al., , 1994b Denny et al., 2005; Perrot-Applanat et al., 1995; Pratt, 1998; Pratt et al., 1999 Pratt et al., , 2004 Pratt and Toft, 1997; Wochnik et al., 2005; Wu et al., 2004) . FKBP52 is a cellular chaperone protein, and ∼80% is localized in the nucleus, and ∼20% in cytoplasm, where it colocalizes with microtubules and dynein, a retrograde motor protein, where the PPIase domain fragment of FKBP52 interacts with dynein (Czar et al., 1994a (Czar et al., , 1994b Perrot-Applanat et al., 1995) . Thus, in addition to studying the interaction of FKBP52 with the D-sequence in the AAV ITR, and its role in inhibiting viral second-strand DNA synthesis in the nucleus, we also wished to examine the role of FKBP52 present in the cytoplasm in AAV-mediated transduction. To this end, we generated primary mouse embryo fibroblasts (MEFs) from FKBP52-wildtype (WT), heterozygous (HE), and knockout (KO) mice, and examined various steps in the life cycle of recombinant AAV vectors in these cells under a variety of conditions. Our studies reported here suggest that, in MEFs, AAV vectors fail to gain entry into the nucleus. Treatment with hydroxyurea (HU) promotes AAV nuclear transport, and FKBP52 can facilitate this process. Thus, in addition to interacting with the D-sequence in the AAV ITR, and inhibiting viral second-strand DNA synthesis in the nucleus, FKBP52, being a cellular chaperone protein, also facilitates intracellular trafficking of AAV, which has implications in the optimal use of recombinant AAV vectors in human gene therapy.
Results
MEFs from WT as well as KO mice are transduced poorly by AAV vectors, which is not due to compensatory binding of a cellular protein to the AAV D-sequence Murine embryo fibroblasts (MEFs) from FKBP52 wildtype (WT), heterozygous (HE), and knockout (KO) mice, established following immortalization using wild-type SV40 virus infections, were either mock infected or infected with a recombinant AAV2-lacZ vectors under identical conditions. β-galactosidase activity was measured 48 h post-infection. These results are shown in Fig. 1A . As is evident, no transgene expression was detected in mock-infected cells, and the transduction efficiency in WT MEFs was low. Although reduction in the levels of FKBP52 in HE and complete absence in KO MEFs were expected to augment viral secondstranded DNA synthesis, the transduction efficiency of AAV vectors was not significantly increased in HE and KO cells. The lack of transgene expression was not a consequence of immortalization by SV40 virus infection since primary MEFs from these mice were also transduced poorly by AAV vectors (data not shown). We next wished to determine whether compensatory binding of a putative cellular protein to the AAV D-sequence in the absence of FKBP52 in KO MEFs was responsible for impaired viral second-strand DNA synthesis. To this end, electrophoretic mobility shift assays (EMSA) were performed using WCEs prepared from MEFs of each genotype. These results are shown in Fig. 1B . As can be seen, the AAV D-sequence probe (Lane 1) formed a complex only with WCEs from WT (Lane 4), and to ∼50% lesser extent in HE MEFs (Lane 3). No complex formation was detected with WCEs from KO MEFs (Lane 2). These data suggested that, in the absence of FKBP52, the observed lack of AAV-mediated transgene expression in KO MEFs was not due to the presence of a cellular protein that compensated for binding to the AAV D-sequence leading to impaired viral second-strand DNA synthesis.
The lack of AAV-mediated transgene expression in MEFs is not due to the absence of cellular receptor and co-receptor required for viral binding and entry
Since it remained possible that suboptimal levels of expression of heparan sulfate proteoglycan (HSPG) and fibroblast growth factor receptor 1 (FGFR1), the cellular receptor and co-receptor, respectively, for AAV (Summerford and Samulski, 1998; Qing et al., 1999) , were responsible for inefficient viral binding and entry into MEFs, we next performed fluorescence-activated cell sorting (FACS) analyses, the results of which are shown in Fig. 2A Briefly, equivalent numbers of each cell type were infected with a recombinant AAV-lacZ vector for 2 h at 37°C and treated with trypsin to degrade any adsorbed viral particles. Low M r DNA samples were analyzed on Southern blots using a lacZ-specific DNA probe. These results are shown in Fig. 2B . The fact that roughly the same level of hybridization to input single-stranded AAV genomes was detected, these data corroborate that AAV could efficiently enter MEFs from each of the three genotypes. Thus, the absence of FKBP52 did not appear to influence viral binding and entry into KO cells. 3 particles/cell of AAV2-lacZ for 2 h at 37°C. Low M r DNA was isolated and analyzed by Southern blot hybridization using a 32 P-labeled lacZ-specific DNA probe. ssDNA denotes the viral single-stranded DNA genomes. Hydroxyurea treatment can increase the transduction efficiency of conventional, single-stranded AAV vectors in WT and HE MEFs, but to a lesser extent in KO MEFs Hydroxyurea (HU) is a chemotherapeutic agent and its mechanism of action is believed to be based on its inhibition of the enzyme ribonucleotide reductase. It has been reported that HU treatment increases AAV-mediated transduction of many cell types by causing S-phase arrest with a concomitant increase in the DNA repair synthesis, which may be crucial for viral second-strand DNA synthesis (Russell et al., 1995) . However, mechanisms other than inhibition of ribonucleotide reductase might be responsible for increasing AAV-mediated transduction. For example, we have reported that the transduction efficiency of AAV vectors can be significantly augmented in the murine established fibroblast cell line, NIH3T3, and in primary hematopoietic stem/progenitor cells following treatment with HU, because HU facilitates nuclear transport of AAV in these cells (Hansen et al., 2001a; Zhong et al., 2004c) as well as leads to dephosphorylation of FKBP52 at tyrosine residues (Qing et al., 1997 Mah et al., 1998) . We wished to examine whether HU could also increase the transduction efficiency of AAV vectors in MEFs. We reasoned that HU would promote AAV trafficking into the nucleus, and would result in higher transduction efficiency in KO MEFs compared with that in WT MEFs because the absence of FKBP52 in the former would facilitate viral second-strand DNA synthesis. Each of the genotype cells was either mock-treated or treated with 10 mM or 40 mM HU for 12 h prior to AAV-mediated transduction, and transgene expression was determined 48 h post-transduction. These results are shown in Fig. 3A . It is evident that treatment with HU did increase the AAV transduction efficiency ∼15-25-fold, in a dose-dependent manner in WT MEFs, and ∼7-fold in HE MEFs. Surprisingly, however, the transduction efficiency in KO MEFs was increased by only ∼3-4-fold (P < 0.001).
Since in our previous studies we had determined that impaired intracellular trafficking of AAV into the nucleus in the NIH3T3 cell line limits high-efficiency transduction of these cells (Hansen et al., 2000 (Hansen et al., , 2001a , we reasoned that the lack of significant increase in AAV transduction of KO MEFs might also be due to inefficient transport of AAV from cytosol into the nucleus. To corroborate this, nuclear and cytoplasmic fractions of MEFs were obtained 48 h post-infection. Low M r DNA was isolated from these fractions and analyzed on Southern blots. These results are shown in Fig. 3B . As can be seen, whereas nearly 100% of the input AAV ssDNA was present in the cytoplasmic fraction in MEFs from all three genotypes (Lanes 2, 4, 6), treatment with HU promoted nuclear transport of AAV in each MEFs (Lanes 7, 9, 11). Densitometric analyses of these data, shown in Fig. 3B , revealed that following HU treatment, AAV DNA in the nuclear fraction increased to ∼58.5% in WT MEFs, whereas in KO MEFs, the increase was only ∼28.1%. These data suggest that, in the absence of FKBP52, treatment with HU is not sufficient for the optimal transport of AAV into the nucleus, which also correlates with the lower transduction efficiency in KO MEFs.
HU treatment can also increase the transduction efficiency of double-stranded, self-complementary AAV vectors in WT and HE MEFs, but to a lesser extent in KO MEFs
In addition to promoting AAV intracellular trafficking, HU can also dephosphorylate FKBP52 and increase AAV secondstrand DNA synthesis (Hansen et al., 2001a (Hansen et al., , 2001b Zhong et al., 2004c) . In order to determine whether the observed lack of increase in the transduction efficiency of AAV vectors in KO MEFs following HU treatment was related to viral second-strand DNA synthesis, we utilized double-stranded, self-complementary AAV (scAAV) vectors that obviate the need for viral second-strand DNA synthesis (McCarty et al., 2001; Wang et al., 2003) . Transduction efficiency of scAAV-EGFP vectors was evaluated 48 h postinfection in WT, HE, and KO MEFs, with and without prior treatment with 40 mM HU. These results are shown in Fig.  4A . As can be seen, although scAAV vectors bypass the requirement of viral second-strand DNA synthesis, the transduction efficiency of these vectors in MEFs of all the three genotypes was still very low, but could be increased by HU treatment. Quantitative analyses of these data, shown in Fig. 4B , indicated that HU treatment increased scAAV vector transduction efficiency in WT MEFs ∼23-fold, but only ∼4-fold in KO MEFs (P < 0.001). These data suggest that the observed differential transduction efficiency of AAV vectors in WT and KO MEFs, following HU treatment, is not directly related to viral second-strand DNA synthesis.
Deliberate expression of FKBP52 in KO MEFs restores the normal response to HU-induced increase in AAV transduction efficiency
To further evaluate the role of FKBP52 in AAV-mediated transduction of MEFs, we generated a eukaryotic expression plasmid containing the human FKBP52 gene under the control of the Rous sarcoma virus promoter (pRSVhFKBP52). Since murine and human FKBP52 share 95% homology (Sanchez et al., 1990; Schmitt et al., 1993) , we reasoned that expression of its human counterpart might be functional in KO MEFs. KO cells were stably transfected with this plasmid to generate KO-T cells, and the levels of expression of FKBP52 were detected by Western blot analyses. These data are shown in Fig. 5A . Densitometric scanning of lumigraphs revealed that the level of expression of FKBP52 in KO-T cells was between the levels of WT and that of HE MEFs. In the next set of experiments, KO and KO-T MEFs were either mock infected or infected with recombinant AAV-lacZ vectors with or without prior treatment with HU, and transgene expression was evaluated 48 h post-infection. These results are shown in Fig. 5B . It is evident that, consistent with our previous data, AAV transduction efficiency was low in KO MEFs (Panel b), and HU treatment had little effect (Panel c). The transduction efficiency was also low in KO-T cells (Panel e), but was significantly increased following HU treatment (Panel f). Nuclear and cytoplasmic fractions of KO and KO-T cells were obtained 48 h post-infection, low M r DNA was isolated from these fractions and analyzed on Southern blots. These results are shown in Fig. 5C . It is evident that, consistent with our previous data, nearly 100% of the input AAV ssDNA was present in the cytoplasmic fraction in KO (Lane 1) as well as in KO-T (Lane 3) cells, treatment with HU promoted nuclear transport of AAV in both cell types (Lanes 6, 8) . Densitometric analyses of these data, shown in Fig. 5D , indicated ) per visual field (mean ± SD). *P < 0.001 versus control, and P < 0.01 versus KO MEFs, **P < 0.001 versus control and KO MEFs.
that the input AAV single-stranded DNA in the nuclear fraction increased from ∼27.2% in KO cells to ∼61.9% in KO-T cells. Thus, FKBP52 is able to restore normal response to HU treatment for AAV-mediated transgene expression in FKBP52-KO MEFs.
Intact AAV capsids associate with FKBP52
We next examined whether FKBP52 also interacts with intact AAV particles to facilitate intracellular trafficking. However, these studies could not be performed in MEFs in view of their low infection as well transfection efficiency, for which 293 cells were used instead. Cells were either mocktransfected or co-transfected with the following three plasmids: recombinant AAV vector (pAAV-hrGFP), an adenovirus helper (pHelper), and an AAV helper (pAAV2-RC) to generate AAV-GFP vectors. Cells were harvested 72 h post-transfection by scraping, and resuspended in a hypotonic buffer. Cytoplasmic fraction was isolated by homogenization in a tight-fitting Duall tissue grinder. Equivalent amounts of cytoplasm were immunoprecipitated with A20 antibodies, which specifically recognize only intact AAV particles with a defined three-dimensional structure (Wistuba et al., 1997; Wobus et al., 2000) , and analyzed on Western blots. Immunoprecipitation with normal mouse IgG antibodies was performed as a negative control. These results are shown in Fig. 6 . As can be seen, intact AAV capsids associate with FKBP52 as well as dynein, known to interact with FKBP52 (Wochnik et al., 2005) . These data document that FKBP52 acts as an accessory protein and may be involved in intracellular trafficking of AAV directly or indirectly through dynein. 
Discussion
It is now firmly established that the viral second-strand DNA synthesis is a major rate-limiting step in AAVmediated transgene expression, and that a cellular protein, FKBP52, is a negative regulator of this step in the virus life cycle (Ferrari et al., 1996; Fisher et al., 1996; Mah et al., 1998; Qing et al., 1997 Qing et al., , 1998 Qing et al., , 2001 Qing et al., , 2003 Zhong et al., 2004a Zhong et al., , 2004b Zhong et al., , 2004c Zhong et al., , 2004d . Although at first glance it seemed intuitive that removal of FKBP52 from cells would augment AAV second-strand DNA synthesis, and consequently, transgene expression, our experimental analyses with cells derived from FKBP52-KO mice, in which FKBP52 was completely absent, documented that the transduction efficiency of AAV vectors was in fact significantly less pronounced than anticipated (Zhong et al., 2004a (Zhong et al., , 2004b (Zhong et al., , 2004c . Counter-intuitively, over-expression of FKBP52 led to a significant increase in the AAV transduction efficiency in a variety of murine and human established cell lines (Qing et al., 2001) .
Since the level of expression of endogenous FKBP52 in semi-permissive murine NIH3T3 cells was found to be significantly lower than that in permissive human 293 cells (data not shown), we wished to determine whether FKBP52 plays an additional role in AAV-mediated transduction in primary murine cells. This was also of interest since in our previous studies, we focused our efforts on the function of FKBP52 localized in the nucleus, but FKBP52 is a cellular chaperone, and it is also localized in the cytoplasm, where it colocalizes with microtubules (Czar et al., 1994a (Czar et al., , 1994b PerrotApplanat et al., 1995) . Although the amount of FKBP52 in the cytoplasm is less than that in the nucleus, it plays crucial roles in intracellular trafficking and/or nuclear transport of a number of cellular and viral proteins, and a number of studies have focused on the function of cytoplasmic FKBP52 (Czar et al., 1994a (Czar et al., , 1994b Denny et al., 2005; Perrot-Applanat et al., 1995; Pratt, 1998; Pratt et al., 1999 Pratt et al., , 2004 Pratt and Toft, 1997; Wochnik et al., 2005; Wu et al., 2004) .
Our previous studies have demonstrated that impaired intracellular trafficking of AAV vectors limits efficient transduction of murine cells, both established and primary, and treatment with HU increased AAV-mediated transduction efficiency in these cells by promoting nuclear transport of AAV (Hansen et al., 2001a; Zhong et al., 2004c) . Our previous studies have also documented that AAV could infect purified nuclei from human and murine cells, and in both instances, could undergo viral uncoating and second-strand DNA synthesis (Hansen et al., 2001b) . Taken together, these studies suggested that a major obstacle to efficient transduction of murine fibroblasts by AAV vectors might exist in the cytoplasm. Thus, murine fibroblasts seemed to be a suitable model to study the intracellular fate of AAV vectors.
Large particles of more than 500 Å, such as viruses and endosomes, are difficult to diffuse in the cytoplasm (Seksek et al., 1997) . Microtubules and microfilaments not only serve as diffusion barriers but also act as "highways" to facilitate the trafficking of these particles to specific destinations such as the nucleus. Details of the intracellular pathway used by AAV are now beginning to be fully understood (Bartlett et al., 2000; Douar et al., 2001; Duan et al., 1999; Hansen et al., 2000 Hansen et al., , 2001a Lux et al., 2005; Seisenberger et al., 2001; Warrington et al., 2004; Xiao et al., 2002) . Some information is available on the relation between AAV intracellular trafficking and microtubules. For example, nocodazoletreatment to depolymerize microtubules prior to AAV infection has been shown to result in >95% reduction in the nuclear accumulation of AAV, and cytochalasin B, which disrupts microfilaments, has also been demonstrated to lead to a dramatic reduction of >90% in the nuclear accumulation of AAV (Sanlioglu et al., 2000) . Trafficking on microtubules destined for either the cell center or the apical domains uses a cytoplasmic protein, dynein, since all endosome mobility ceased when dynein function was disrupted by the use of a mutant dynein heavy chain allele (Mallik and Gross, 2004; Murray and Wolkoff, 2003; Welte, 2004) . Previous studies have shown that cytoplasmic dynein is less efficient and robust in achieving the comparable function to the other motors; and that it requires a number of accessory proteins as well as multiple dyneins functioning together (Welte, 2004) . Information on the role of dynein in intracellular trafficking of parvoviruses is beginning to emerge (Suikkanen et al., 2002) . For example, Xu et al. (2005) have reported that inefficient entry of AAV into NIH3T3 cells could be overcome by inserting a motif in the capsid predicted to promote binding to the LC8 subunit of the dynein motor complex. Additional studies have also documented that FKBP52 can bind either directly or via a linker protein with the cytoplasmic dynein; the PPIase domain fragment of FKBP52 interacts with dynein, and provides a link between the glucocorticoid receptor-HSP90 heterocomplex and cytoplasmic dynein for retrograde movement along microtubules (Galigniana et al., 2001) . Unfortunately, virtually nothing is known about the role of FKBP52 on AAV intracellular trafficking. In our current studies, the association of AAV capsids with FKBP52 and dynein could be documented by co-precipitation with A20 antibodies, which specifically recognize only intact AAV particles with a defined threedimensional structure. Although our data provide only indirect evidence for the role of FKBP52 as a nuclear chaperone for AAV in MEFs since it remains possible that the observed interaction between FKBP52, dynein, and AAV might be due to the combined effects of HU and FKBP52. However, since co-immunoprecipitation assays were carried out in the absence of HU in 293 cells, we believe that the observed interactions between FKBP52, dynein, and AAV are direct. Additional co-localization studies involving confocal microscopy will be needed to corroborate these observations. AAV vectors failed to gain entry into the nucleus, and consequently failed to transduce primary murine fibroblasts. Complete removal of FKBP52 did not lead to increased transgene expression in these cells. However, FKBP52 facilitated the nuclear transport of AAV in the presence of HU in murine cells. We hypothesize that FKBP52 plays a dual role in the life cycle of AAV: the cytoplasmic FKBP52, presumably in its unphosphorylated form, helps facilitate the intracellular transport of the virus; and the nuclear FKBP52, in its phosphorylated form, strongly inhibits the viral second-strand DNA synthesis.
In sum, in addition to interacting with the D-sequence in the AAV ITR and inhibiting viral second-strand DNA synthesis, FKBP52, being a cellular chaperone protein, also facilitates intracellular trafficking of AAV. It is of interest to further explore whether the phosphorylation status of FKBP52 is a determining factor. A better understanding of the underlying molecular mechanism of intracellular trafficking of AAV should have important implications in the optimal use of recombinant AAV vectors in human gene therapy.
Materials and methods

Cells, viruses, and plasmids
Murine embryo fibroblasts (MEFs) were cultured as previously described (Horak and Flechon, 1998; Mukherjee et al., 1984) . In brief, 12-14 day old embryos were obtained, and a small amount of tissue was used for PCR analysis to detect the FKBP52 genotypes. Fibroblasts were derived from embryos by drawing each embryo through a 10 ml syringe fitted with an 18 gauge needle. After washing, the cells were cultured in 10 cm tissue culture dishes in MEF growth media consisting of DMEM/F12 media (Gibco, Carlsbad, CA) containing 10% fetal bovine serum and 1% (by volume) 100× stock solution of antibiotics (10,000 U of penicillin plus 10,000 μg of streptomycin) supplemented with 2 mM Lglutamine. MEFs were immortalized at passage 3 following infection with wild-type SV40 virus at a multiplicity of infection (MOI) of 50. Immortalization had no significant effect on AAV-lacZ transduction efficiency (data not shown).
Highly purified stocks of a recombinant AAV2 vector containing the β-galactosidase (lacZ) reporter gene driven by the cytomegalovirus (CMV) immediate-early promoter (AAV2-lacZ) were obtained from Applied Viromics LLC, Fremont, CA. Self-complementary recombinant AAV2 vectors containing the CMV promoter-driven EGFP (scAAV2-EGFP) were generously provided by Dr. R. Jude Samulski, University of North Carolina at Chapel Hill. A recombinant expression plasmid containing the Rous sarcoma virus (RSV) promoter-driven human FKBP52 cDNA (pRSV-hFKBP52) was constructed by standard cloning methods.
Recombinant AAV2-mediated transduction assays
Approximately 8 × 10 4 or 3 × 10 5 MEFs were plated in each well in 12-well or 6-well plates, respectively, and incubated at 37°C for 12 h. Cells were washed once with DMEM/F12 media and then infected at 37°C for 2 h with mock and 5 × 10 3 particles per cell of recombinant AAV2-lacZ or scAAV2-EGFP as described previously (Qing et al., 1997 (Qing et al., , 1999 (Qing et al., , 2001 (Qing et al., , 2003 . Forty-eight hours after AAV2-lacZ infection, cells were fixed and stained with X-gal (5-bromo-4-chloro-3-indolyl β-Dgalactopyranoside) and the blue cells were counted, or β-galactosidase activity was measured by Galacto-Light Plus chemiluminiscence reporter assay (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. Data were expressed as relative light units (RLU) per microgram of total protein and were within the linear range of the assay. The transduction efficiency of scAAV2-EGFP was measured by GFP imaging using a Zeiss Axiovert 25 fluorescence microscope (Carl Zeiss, Inc., Thornwood, NY). Images from three visual fields of mock-infected and vector-infected MEFs cells 48 h post-injection were analyzed quantitatively by ImageJ analysis software (NIH, Bethesda, MD). Transgene expression was assessed as total area of green fluorescence (pixel 2 ) per visual field (mean ± SD).
Preparation of whole cell extracts (WCEs) and electrophoretic mobility-shift assays (EMSA)
WCEs from MEFs were prepared according to the method of Muller (1987) . Total protein concentration was determined by the Bio-Rad protein assay kit (Bio-Rad, Hercules, CA), and the extracts were frozen in liquid N 2 and stored at −70°C. EMSA were performed as described previously (Qing et al., 1997 (Qing et al., , 2001 (Qing et al., , 2003 Zhong et al., 2004d) . Briefly, DNAbinding reactions were performed in a volume of 20 μl with 2 μg of poly (dI-dC), 2 μg of bovine serum albumin, and 12% glycerol in Tris buffer (10 mM Tris-HCl, 0.5 mM dithiothreitol, 25 mM NaCl, 5 mM MgCl 2 , 0.05% Nonidet P-40 [NP40], pH 8.0). Ten micrograms of protein of each WCEs was pre-incubated for 10 min at 25°C followed by the addition of 10,000 cpm of 32 P-labeled D-sequence synthetic oligonucleotide (5′-AGGAACCCCTAGTGATGGAG-3′) in the reaction mixture. The binding reaction was allowed to proceed for 30 min at 25°C. Bound complexes were separated from the free probe on low ionic strength 4% polyacrylamide gels with Tris-glycine/EDTA buffer, pH 8.5, containing 50 mM TrisHCl, 380 mM glycine, and 2 mM EDTA. Following electrophoresis, the gel was dried in vacuum and autoradiographed using Kodak X-Omat film at −70°C.
Southern blot analyses for AAV internalization
Approximately 3 × 10 6 MEFs from each genotype were either mock-infected or infected with 3 × 10 3 particles/cell of AAV2-lacZ for 2 h at 37°C after which cells were treated with 0.01% trypsin and washed extensively with PBS to remove any adsorbed and unadsorbed virus particles. Low M r DNA was isolated and electrophoresed on 1% agarose gels followed by Southern blot hybridization with a 32 P-labeled lacZ-specific DNA probe as described previously (Hansen et al., 2000 (Hansen et al., , 2001a .
Isolation of nuclear and cytoplasmic fractions from MEFs and Southern blot analyses for AAV intracellular trafficking
Nuclear and cytoplasmic fractions from MEFs were isolated as described previously (Hansen et al., 2000 (Hansen et al., , 2001a Zhong et al., 2004c) . Briefly, MEFs mock infected or infected with the recombinant AAV-lacZ vectors were washed twice with PBS. The cell pellets were gently resuspended in 200 μl of homogenization buffer (0.25 M sucrose, 10 mM triethanolamine, pH 7.6, 1 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride [PMSF] ) and incubated on ice for 5 min, after which 10 μl of 10% NP-40 was added to each tube and cells were observed under a light microscope for about 2 min. The samples were then mixed gently and centrifuged for 5 min at 500 rpm at 4°C. The supernatants (cytoplasmic fraction) were decanted and stored on ice. The pellets (nuclear fractions) were washed twice with 1 ml of homogenization buffer and stored on ice. The purity of each fraction was determined to be >95%, as measured by the absence of acid phosphatase activity (nuclear fractions) and the absence of histone H3 (cytoplasmic fractions) as described previously (Hansen et al., 2000 (Hansen et al., , 2001a Zhong et al., 2004c) . Low M r DNA samples from nuclear and cytoplasmic fractions were isolated and electrophoresed on 1% agarose gels followed by Southern blot as described above. Densitometric scanning of autoradiographs, for the quantitation of relative amounts of viral genomes, was evaluated with ImageJ analysis software.
Stable transfection with FKBP52 expression plasmids
Approximately 4 × 10 5 MEFs from FKBP52-KO mice were seeded into each well in a 6-well plate in DMEM/F12 media (Gibco, Carlsbad, CA) containing 10% fetal bovine serum for 24 h prior to transfection. Four micrograms of pRSV-FKBP52 was added to cells using Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Cells were cultured in the selective media containing 300 mg/ml hygromycin (Invitrogen) 48 h after transfection. Clones containing FKBP52 vectors were obtained after 28 days of selection.
Immunoprecipitations and Western blot analyses
To determine the levels of FKBP52 in MEFs from FKBP52-WT, HE, and KO mice, and in MEFs from FKBP52-KO mice stably transfected with FKBP52 expression plasmid, approximately 3 × 10 6 cells were seeded in culture dishes, and 24 h later, WCEs were prepared. Total protein concentrations were determined using the Bio-Rad protein assay kit, and 40 μg of protein was separated by SDS-polyacrylamide gel electrophoresis on a 10% polyacrylamide gel. After transfer to an Immobilon-P membrane (Millipore, Bedford, MA), the membrane was blocked at 25°C for 1 h with 5% nonfat dry milk in 1× Tris-buffered saline (TBS; 20 mM Tris-HCl, pH 7.5, 150 mM NaCl), and 0.05% Tween 20, then incubated with a 1:500 dilution of anti-FKBP52 antibody for 1 h at 25°C. Following incubation with 1:5000 dilution of horseradish peroxidase-coupled anti-rabbit IgG antibody for at 25°C 1 h and protein bands were visualized with the ECL-Plus chemiluminiscence detection kit (Amersham Biosciences, Piscataway, NJ) according to the instructions provided by the manufacturer.
For immunoprecipitation, five 150 mm plates 293 cells were triple transfected by pAAV-hrGFP, pHelper, and pAAV2-RC to produce AAV vector with lipofectamine, and the cells were harvested at 72 h post-transfection by scraping and resuspended in 2 ml hypotonic buffer (20 mM HEPES pH 7.5, 5 mM KCl, 0.5 mM MgCl 2 , 1 mM DTT, 0.1 mM PMSF, 2 mM pepstatin A), and the cytoplasm was isolated by homogenization in a tight-fitting Duall tissue grinder until about 80% cell lysis was achieved as monitored by trypan blue. Equivalent amounts of cytoplasm were cleared of nonspecific binding by incubation with 0.25 mg of normal mouse IgG together with 20 μl of protein G-agarose beads for 60 min at 4°C in an orbital shaker. After pre-clearing, 2 μg of A20 antibody (mouse IgG) or 2 μg of normal mouse IgG (as a negative control) was added and incubated at 4°C for 1 h, followed by precipitation with protein G-agarose beads at 4°C for 12 h in the shaker. Pellets were collected by centrifugation at 2500 rpm for 5 min at 4°C and washed four times with phosphate-buffered saline. After the final wash, the supernatant was aspirated and discarded, and the pellet was resuspended in equal volume of 2× SDS sample buffer. Twenty microliters of resuspended pellet solutions was used for Western blotting with anti-B1, anti-FKBP52 and antidynein intermediate chain antibodies (Sigma, USA).
